anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This clinical project will be carried out in the operating rooms of the University Hospital and the Doctors Office Center. The study will be done during routine surgery where a laryngeal mask airway will be used to maintain airway during general anesthesia in 20 adult patients with American Society of Anesthesiologists physical status I or II. Routine anesthetic care standards will be applied in intravenous line placement and monitoring of patients. General anesthesia will be induced with a bolus dose of propofol (2mg.kg-1) and maintained with an intravenous infusion of propofol (100-200 mcg.kg-1.min-1). Patients will be allowed to breathe spontaneously 40% oxygen in air. Adjuvant intravenous medications will be given for amnesia, analgesia and infection prophylaxis as per routine anesthetic practice. The ambient propofol concentration will be measured, using a proton transfer reaction mass spectrometer (PTR-MS), at a distance of 25cm from the patient's face. The measurement of ambient propofol concentration will begin before the administration of propofol to the patient and will continue till the patient leaves the operating room. The use of PTR-MS device will not interfere with the anesthetic management of patient. In an unforeseen circumstance, where the anesthesiologist determines the use of PTR-MS does interfere with the anesthetic care of the patient, the device will be immediately removed and the measurement of ambient propofol concentration will be suspended for the case. The set-up and usage of PTR-MS will be performed by a research team that does not take part in the clinical management of the patient. The PTR-MS is a device that depends on the proton transfer reaction to quantify, in parts per billion (ppb) by volume, volatile organic compounds in air at extremely low concentrations and in real time. The mean and peak ambient propofol concentration will be determined during each case and a time weighted average (TWA) will be calculated for an eight-hour period at the end of the study. In addition, after receiving written informed consent from anesthesia care providers, blood samples will be drawn from them and propofol concentrations will be measured by high-performance liquid chromatography (HPLC) within 24hr. The blood samples will constitute 3ml on two occasions, one early in the morning before anesthesia care starts and one after eight hours of anesthesia care. HPLC is a device that uses a spectrofluorometric detector to estimate trace amounts of propofol in blood in ng.ml-1. The blood estimation of propofol will also be conducted by a research team that does not take part in the clinical management of patients.
The present disclosure provides for modeling a clinical trial study, which may implement a cross-over design. A plurality of treatments is generated for a clinical trial study, based on a first subset of operational parameters. A plurality of sequences is also generated for the clinical trial study, based on a second subset of the operational parameters. Each sequence of the plurality of sequences comprises a combination of ones of the plurality of treatments. A plurality of subject groups is assigned to the plurality of sequences, where one subject group of the plurality of subject groups is respectively assigned to one sequence of the plurality of sequences. The one sequence is administered to subjects of the one subject group during the clinical trial study.
BACKGROUND: Endocrine therapy resistance in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC) is a significant clinical challenge that poses several unmet needs in the management of the disease. This study aimed to investigate the prognostic value of c-MET-positive circulating tumor cells (cMET+ CTCs), ESR1/PIK3CA mutations, and cell-free DNA (cfDNA) concentrations in patients with hormone receptor-positive (HR+) metastatic breast cancer (mBC).
METHODS: Ninety-seven patients with HR+ mBC were prospectively enrolled during standard treatment at Samsung Medical Center. CTCs were isolated from blood using GenoCTC® and EpCAM or c-MET CTC isolation kits. PIK3CA and ESR1 hotspot mutations were analyzed using droplet digital PCR. CfDNA concentrations were calculated using internal control copies from the ESR1 mutation test. Immunocytochemistry was performed to compare c-MET overexpression between primary and metastatic sites.
RESULTS: The proportion of c-MET overexpression was significantly higher in metastatic sites than in primary sites (p = 0.00002). Survival analysis showed that c-MET+ CTC, cfDNA concentration, and ESR1 mutations were significantly associated with poor prognosis (p = 0.0026, 0.0021, and 0.0064, respectively) in HR+/HER2- mBC. By contrast, EpCAM-positive CTC (EpCAM+ CTC) and PIK3CA mutations were not associated with progression-free survival (PFS) in HR+/HER2- mBC. Multivariate analyses revealed that c-MET+ CTCs and cfDNA concentration were independent predictors of PFS in HR+/HER2- mBC.
CONCLUSIONS: Monitoring c-MET+ CTC, rather than assessing c-MET expression in the primary BC site, could provide valuable information for predicting disease progression, as c-MET expression can change during treatment. The c-MET+ CTC count and cfDNA concentration could provide complementary information on disease progression in HR+ /HER2- mBC, highlighting the importance of integrated liquid biopsy.
Participant will receive single oral dose of evobrutinib within 30 minutes after start of a light meal (Treatment B) for 3 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days. There will be 48 hours washout period between each treatment period.
Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules.
Absorbable sutures are more cost efficient and eliminate the need for suture removal both reducing costs and abolishing suture removal pain. We will study the difference in the visual outcome between the two groups. Based on former study the primary hypothesis is that there is no difference between the groups. The patients will evaluate their scars on a VAS-scale one year after the surgery. Secondarily we will focus on pain caused by the two sutures and take the suture removal pain into consideration. We expect therefore the non-absorbable suture to cause more pain in total. The evaluation will happen 2 weeks after the surgery by the patients.
BACKGROUND: Interventions that use the Health Action Process Approach (HAPA) model show promise for increasing PA frequency, duration, and intensity. However, there is limited understanding of how HAPA model variables have been operationalized for PA interventions in chronic disease to promote behavior change and sustained PA or whether the phase or continuous form of the HAPA model was used. The aim of this scoping review is to describe how the HAPA model variables for PA interventions were operationalized and provide details of implementation.
METHOD: We searched five databases to identify studies published between January 1992 and March 2024. We aimed to describe (1) the characteristics of interventions including setting, delivery mode, duration, and content; (2) which HAPA variables were operationalized and the strategies used; and (3) the physical activity measures and outcome effects.
RESULTS: The search identified 23 interventions in 30 papers (12 protocols, 3 quasi-experimental studies, and 15 randomized controlled trials (RCTs)). Seven of the 15 RCTs reported significant positive effects of the HAPA model on PA behavior outcomes. Interventions operationalized between three and nine HAPA constructs showed significant variability in how the HAPA model is used in intervention research. PA measures varied from self-report to validated objective instruments.
CONCLUSION: We found a lack of clarity in decisions about which HAPA constructs were included in interventions. The wide variability in operationalized HAPA constructs made it challenging to compare interventions. Researchers should provide more detail about intervention design and implementation procedures to enhance transparency.
Analysis of the adverse events in a population consisting of 942 patients in 3 clinical studies diagnosed with myeloproliferative diseases of varying etiology (ET: 551; PV: 117; OMPD: 274) has shown that all disease groups have the same adverse event profile. While most reported adverse events during anagrelide therapy have been mild in intensity and have decreased in frequency with continued therapy, serious adverse events were reported in these patients. These include the following: congestive heart failure, myocardial infarction, cardiomyopathy, cardiomegaly, complete heart block, atrial fibrillation, cerebrovascular accident, pericarditis, pericardial effusion, pleural effusion, pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension, pancreatitis, gastric/duodenal ulceration, and seizure.

Of the 942 patients treated with anagrelide for a mean duration of approximately 65 weeks, 161 (17%) were discontinued from the study because of adverse events or abnormal laboratory test results. The most common adverse events for treatment discontinuation were headache, diarrhea, edema, palpitation, and abdominal pain. Overall, the occurrence rate of all adverse events was 17.9 per 1,000 treatment days. The occurrence rate of adverse events increased at higher dosages of anagrelide.

The most frequently reported adverse reactions to anagrelide (in 5% or greater of 942 patients with myeloproliferative disease) in clinical trials were:

Adverse events with an incidence of 1% to < 5% included:
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC), a secondary agent, and optionally an anti-CD20 agent. The Antibody Drug Conjugates target CD19 or CD22 and are disclosed for the treatment of cancers. Methods for identifying an individual as suitable for treatment by selecting patient if he/she is or has been treated with an anti-CD20 agent such as rituximab are disclosed. Optionally, the ADC is administered in combination with a further agent, e.g. a chemotherapeutic agent.
Following a classic inguinal incision of approximately 5-7 cm extending laterally from the pubic tubercle, the external oblique aponeurosis was opened, the external ring was disrupted, and the spermatic cord/round ligament was suspended. The hernia sac was isolated from surrounding tissues and the spermatic cord/round ligament, then either reduced or ligated. Subsequently, a polypropylene mesh measuring approximately 60x110 mm² was placed to completely cover the transverse fascia, and continuous sutures were used to secure it laterally along the transverse arch starting from the pubic tubercle. Hemostasis was achieved, and the layers and skin were anatomically closed.
This study is a parallel-group, blinded (blinding applies to participants, evaluators, investigators, and statisticians) randomized controlled trial designed to explore the preventive effect of electroacupuncture combined with self-administered acupressure plus doctor-prescribed treatment on HFS in patients with malignant tumors receiving oral capecitabine and to improve the quality of life for patients during treatment. Participants are randomly assigned to one of two groups: a true electroacupuncture combined with true self-administered acupressure group, or a sham electroacupuncture combined with sham self-administered acupressure group. The true electroacupuncture combined with true self-administered acupressure group receives true electroacupuncture combined with true self-administered acupressure plus doctor-prescribed treatment(oral administration of celecoxib, external application of diclofenac, and other skin protectants). The sham electroacupuncture combined with sham self-administered acupressure group receives sham electroacupuncture combined with sham self-administered acupressure plus the same doctor-prescribed treatment. HFS will be assessed following the initiation of capecitabine treatment, with records kept of the capecitabine dosage, the severity of HFS, onset time, and duration of symptoms. In addition, the HFS-14 questionnaire was used to assess the condition of patients at each cycle.
Dementia is a syndrome caused by diseases of the cerebral parenchyma, and it is a state in which cognitive functions, including attention, memory, thinking, comprehension, judgment, and computation, are diminished. Because of the mental symptoms, problem behaviors, and decreased activities of daily living (ADL) it is also recognized as a major social problem. However, rehabilitation of elderly people with dementia is still at the trial-and-error stage, and establishing a method of rehabilitation is an urgent task. In 2004, the authors devised and created a training method that integrates exercise therapy with feedback therapy to treat the cognitive dysfunction of elderly people with dementia. To do so the authors introduced speed-feedback therapy with a bicycle ergometer as a feedback therapy intervention. The results of a preliminary study of the efficacy of this method in improving cognitive dysfunction in 17 elderly persons with dementia showed improvement in cognitive dysfunction, and their attentiveness also improved, suggesting that the impaired attentiveness may have improved in response to treatment by this method and, as a result, have led to improvement of cognitive dysfunction. However, it became clear that it would be necessary to further improve and develop the system, and to demonstrate its efficacy in a controlled trial and verify associations between improvement of cognitive dysfunction and improvement of the ADL of dementia patients and their quality of life (QOL).
PROBLEM TO BE SOLVED: To atomize a liquid to be atomized widely in response to characteristic of the liquid to be atomized or a particle diameter range of automation by a method wherein a second injection hole is arranged at an outer circumference flow of a first injection hole and a circulating means for making a circulating of each of gas and liquid is arranged at forward portions of these first and second injection holes. SOLUTION: A liquid feeding hole 10b of slight fine diameter subsequent to a liquid feeding hole 104 of a base section 103 is formed and an extremity end of an intermediate section 102 of the base section 103 forms an extremity end head part 101 of which diameter is expanded. A first injection hole 107 for injecting liquid inside the extremity end head 101 is formed. Then, an annular vortex flow chamber 110 is formed at an outer circumference of the first liquid injection hole 107 and a forward part of the vortex flow chamber 110 is communicated with a second injection hole 111 of narrow clearance for injecting annular gas. Forward portions of these first and second injection holes 107 and 111 and provided with whirling means 108 and 117 for making each of whirling flows of gas and liquid.  With such an arrangement as above, it becomes possible to perform an atomization under a moderate condition.
(Background): Cadmium is an environmental pollutant associated with several liver diseases. Baicalin and N-Acetylcysteine have antioxidant and hepatoprotective effects. (Purpose): However, it is unclear whether baicalin and N-Acetylcysteine can alleviate Cadmium -induced liver fibrosis by regulating metabolism, or whether they exert a synergistic effect. (Study design): We treated Cadmium-poisoned mice with baicalin, N-Acetylcysteine, or baicalin+ N-Acetylcysteine. We studied the effects of baicalin and N-Acetylcysteine on Cadmium-induced liver fibers and their specific mechanisms. (Methods): We used C57BL/6 J mice, and AML12, and HSC-6T cells to establish in vitro assays and in vivo models. (Results): Metabolomics was used to detect the effect of baicalin and N-Acetylcysteine on liver metabolism, which showed that compared with the control group, the Cadmium group had increased fatty acid and amino acid levels, with significantly reduced choline and acetylcholine contents. Baicalin and N-Acetylcysteine alleviated these Cadmium-induced metabolic changes. We further showed that choline alleviated Cadmium -induced liver inflammation and fibrosis. In addition, cadmium significantly promoted extracellular leakage of lactic acid, while choline alleviated the cadmium -induced destruction of the cell membrane structure and lactic acid leakage. Western blotting showed that cadmium significantly reduced mitochondrial transcription factor A (TFAM) and Choline Kinase α(CHKα2) levels, and baicalin and N-Acetylcysteine reversed this effect. Overexpression of Tfam in mouse liver and AML12 cells increased the expression of CHKα2 and the choline content, alleviating and cadmium-induced lactic acid leakage, liver inflammation, and fibrosis. (Conclusion): Overall, baicalin and N-Acetylcysteine alleviated cadmium-induced liver damage, inflammation, and fibrosis to a greater extent than either drug alone. TFAM represents a target for baicalin and N-Acetylcysteine, and alleviated cadmium-induced liver inflammation and fibrosis by regulating hepatic choline metabolism.
The invention discloses a traditional Chinese medicine preparation for treating breast hyperplasia. The preparation is composed of the following active pharmaceutical ingredients of, by weight, 5-15 parts of cinnamon, 5-15 parts of fennel fruit, 3-9 parts of bupleurum scorzonerifolium willd, 3-9 parts of pericarpium citri reticulatae viride, 3-9 parts of pericarpium citri reticulatae, 5-15 parts of rhizoma chuanxiong, 5-15 parts of radix paeoniae rubra, 5-15 parts of raw white mustard seed, 5-15 parts of aiomatic turmeric root-tuber, 5-15 parts of zhi cyperus rotundus, 3-9 parts of fructus amomi and 3-9 parts of borneol. The traditional Chinese medicine preparation is prepared by taking all the active pharmaceutical ingredients, mixing, smashing into medicine powder and sieving with 200 meshes. When the preparation is in use, the medicine powder is loaded in a 10 cm*10 cm medicine bag made of a single layer undershirt cloth, and the medicine can be separated by sewing two lines in the middle of the medicine bag to prevent the medicine powder from accumulation. In treatment, the medicine bag is fixed in a brassiere of a patient, and is changed every week, with half a month as one course of the treatment. Patients in a less severe state can be cured in 2-3 courses, while patients in a severe state can be cured in 5-6 courses.
Medicaments for use in human and veterinary medicine contain oligo- or polynuclear molecules consisting of FeII or FeIII atoms linked together by one or more OH or O bridges. A typical medicament, comprising a polymeric cpd. in which the Fe atoms are linked by double OH bridges and coordinated with bidentate glucose ligands, is prepd. by heating a 0.005M soln. of Fe ions at 80-100 degrees C and treating with 0.28M glucose soln. The medicaments can be used to treat bacterial, fungal and viral infections, inflammations not detectably induced by microorganisms, acute and chronic inflammatory disorders of the lymphatic system, quinsy and chronic tonsillar inflammations. They also have some antineoplastic activity. The medicaments activate the body's defence mechanism without causing allergic or toxic side effects and without inducing resistance in microorganisms.
PURPOSE:A stick-shaped powder cosmetic that is prepared by combining a mixture of talc and kaolin in a specific proportion as a powder base with additional magnesium stearate, thus showing good spread on skins and comfortable feel on use and having good moldability and form retention. CONSTITUTION:A stick-shaped powder cosmetic is composed of talc, kaolin and magnesium stearate wherein the weight ratio of talc and kaoling is 4/6-6/4, the total amount of talc and kaoling is 50-90, preferably 60-80wt% and the magnesium stearate is more than 4%, preferably 6-12% on the basis of the total weight of the cosmetic. The composition is compressed into sticks, which are used as cosmetic. The preferably prssure on the compression is 50-200kg/cm<2>. The addition of an anhidrotic permits the molded product to be used as an anhidrotic stick. USE:Deodorant powder, baby powder, shaving powder, eye-shadow powder and so on.
PURPOSE OF REVIEW: This review focuses on the association between RA and heart failure, highlighting the role of inflammation and the prevalence of heart failure with preserved ejection fraction (HFpEF) in this population.
RECENT FINDINGS: The incidence of heart failure in RA patients is two to three times higher than in the general population, with inflammation playing a significant role independent of traditional cardiovascular risk factors. HFpEF accounts for about half of heart failure cases and is increasingly recognized in RA patients, although it remains underdiagnosed. Atypical presentations and non-specific symptoms further complicate diagnosis. Early control of inflammation has been shown to reduce the risk of heart failure development and progression, improving both morbidity and mortality outcomes. Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting approximately 1% of the population, with cardiovascular disease being the leading cause of premature death in these patients.
Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.
PURPOSE:To explain the caloric intake of each nutritive element to each person in an easy-to-understand way by calculating the individual intake of nutritive elements and displaying or printing the caloric intake of each nutritive element in a list every plural color groups based on the result of calculation. CONSTITUTION:The 1st and 2nd master files 12a and 12b, an individual informa tion file 13, an input device 14, a display 15, a printer 16, etc., are connected to a computer 11 via buses. Then the intensity of the daily life activity, the types of foods included in each meal, and the caloric intake are inputted. These inputted data are accumulated for a fixed time. Then the nutritive elements contained in the taken foods are calculated based on the accumulated data, and the taken foods are divided into plural color groups according to the dieteti cal features of foods. Then the caloric intake of each nutritive element is dis played 15 and printed out 16 for each color group in a list together with the necessary caloric intake calculated from the information on the sex, the age, the height, the intensity of the daily life activity, etc., of each person. Thus, it is possible to explain the caloric intake of each nutrivie element to each person in an easy-to-understand way.
Olfactory training by neurological chemosensory stimulation using aromatic substances delivered via diffusers. Four aromatic substances will be used. Each substance will be given for 20 seconds sequentially, providing a total of 80 seconds of olfactory stimulation three times per day for 3 months.
Surgery: a "reverse" end-to-side AIN to ulnar nerve transfer whereby the motor branch of the ulnar is left intact and the end of the AIN nerve is coapted to the side of the ulnar motor fascicle(5,6). The advantage of this technique is it preserves the continuity of the ulnar motor branch for axons if they do eventually reinnervate the intrinsic muscles while augmenting or "babysitting" these muscles during the time period until this occurs.